Medical management of chronic subdural hematoma with tranexamic acid

We read with great interest the research work by Kutty RK and colleagues1 on medical management with Tranexamic Acid (TXA) for chronic subdural hematoma (CSDH). We appreciate the authors for successfully demonstrating a possible role for TXA in non-surgical management of CSDH with hematoma volumes ranging from as small as 25mL up to a volume of 350mL. That oral TXA use ranging from 27-120 days after diagnosis of CSDH provides resolution of hematoma with no complications is a novel contribution to knowledge; nevertheless we have a few suggestions on patient inclusion and methodology of the study.

Source: Journal of Stroke and Cerebrovascular Diseases - October 20, 2020 Category: Neurology Authors: Varun Suresh, Saurabh Sharma Tags: Letter to the Editor Source Type: research